// App-Quantinova.ai

620 : Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Second Interim Analysis of OPAL Balance, an Open‑Label, Long-Term Extension Study

Researchers

Presenter

  • Peter Nash

Principal Investigators

  • Laura C Coates

  • Alan J. Kivitz

  • Philip J Mease

  • Dafna D Gladman

  • Jose A Covarrubias-Cobos

  • Dona Fleishaker

  • Cunshan Wang

  • Elizabeth Kudlacz

  • Sujatha Menon

  • Thijs Hendrikx

  • Keith S Kanik

Medical Centers

  • Department of Medicine, University of Queensland, Brisbane, Queensland, Australia

  • Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, United States

  • Swedish Medical Center and University of Washington School of Medicine, Seattle, WA

  • Department of Medical Imaging, University of Toronto, Toronto General Hospital, Toronto, ON, Canada

  • Unidad Reumatologica Las Americas S.C.P., Merida, Mexico

  • Pfizer, Groton, CT

  • Pfizer Inc, Collegeville, PA

Locations

  • Australia

  • United Kingdom

  • United States

  • Canada

  • Mexico

Companies

  • Pfizer Inc.

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Tasocitinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01976364

  • NCT01882439

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved